Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Private pharmaceutical manufacturer · Karachi · Pakistan
Pakistan pharmaceutical manufacturer founded in 1973 with domestic production and an international market presence.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- ZAFA Pharmaceutical Laboratories (Private) Limited
- Company type
- Private pharmaceutical manufacturer
- Address
- L-1/B, Block-22, Federal B Industrial Area, Karachi-75950, Pakistan · 75950
- Website
- zafa.com.pk ↗
- Phone
- +92 21 36807100
- contact@zafa.com.pk
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Sodium Chloride 0.9% | Sodium chloride | 0.9 % | Injection | 1's | 057805 | PKR 18.71 | PKR 18.71/vial/unit | No comparator |
| Sofozaf | Sofosbuvir | 400 mg | Tablet | 28's | 112795 | PKR 8,154.99 | PKR 291.25/tablet | 33% below median |
| Testonon | Testosterone propionate + Testosterone phenylpropionate + Testosterone isocaproate + Testosterone decanoate | 30 mg + 60 mg + 60 mg + 100 mg | Injection | 1ml | 042403 | PKR 103.27 | PKR 103.27/mL | No comparator |
| Tropum Nebuliser | Ipratropium bromide | 0.5 mg/2 mL | Nebuliser solution | 5 X 2ml | 053011 | PKR 639.83 | PKR 63.98/mL | 22% above median |
| Vancomycin | Vancomycin | 500 g | Injection | 1 | 103021 | PKR 1,292.61 | — | No comparator |
| Vancomycin | Vancomycin | 1 g | Injection | 1's | 103022 | PKR 2,086.64 | PKR 2,086.64/vial/unit | 11% above median |
| Virquin | Chloroquine | 250 mg | Tablet | 50 x 10's | 101340 | PKR 863.65 | PKR 1.73/tablet | 12% above median |
| Vofloza | Levofloxacin | 250 mg | Tablet | 10's | 050771 | PKR 516.33 | PKR 51.63/tablet | 6% above median |
| Vofloza | Levofloxacin | 500 mg | Tablet | 10's | 055546 | PKR 859.19 | PKR 85.92/tablet | 9% above median |
| Water For | Water for Injection | 20 mL | Injection | 20ml | 057809 | PKR 22.79 | PKR 1.14/mL | 9% below median |
| Water for Injection | Water for Injection | 5 mL | Injection | 5ml | 057807 | PKR 14.63 | PKR 2.93/mL | 47% above median |
| Water for Injection | Water for Injection | 10 mL | Injection | 10ml | 057808 | PKR 12.19 | PKR 1.22/mL | 42% below median |
| Xynosine | Xylometazoline | 0.1% | Nasal spray | 15ml | 000865 | PKR 75.51 | PKR 5.03/mL | 132% above median |
| Xynosine | Xylometazoline | 0.1% | Nasal spray | 10 ml | 000865 | PKR 21.69 | PKR 2.17/mL | 57% below median |
| Xynosine | Xylometazoline | 0.05% | Nasal spray | 15ml | 023329 | PKR 60.79 | PKR 4.05/mL | No comparator |
| Yes 2 | Zinc | 10 mg/5 mL | Syrup | 60ml | 039789 | PKR 95.96 | PKR 1.60/mL | No comparator |
| Yes 2 | Zinc | 20 mg/5 mL | Dry suspension | 60ml | 053119 | PKR 106.64 | PKR 1.78/mL | 11% below median |
| Yes 2 | Zinc | 20 mg/5 mL | Syrup | 60ml | 053335 | PKR 106.64 | PKR 1.78/mL | Near median |
| Zaclazide | Gliclazide | 80 mg | Tablet | 20’s | 015614 | PKR 186.36 | PKR 9.32/tablet | 18% below median |
| Zad | Cholecalciferol | 5 mg | Injection | 1s | 083982 | PKR 222.20 | PKR 222.20/vial/unit | 15% above median |
| Zafacain | Cefazolin | 500 mg | Injection | 1’s | 047441 | PKR 127.96 | PKR 127.96/vial/unit | 6% above median |
| Zafacain | Cefazolin | 1 g | Injection | 1’s | 047442 | PKR 227.19 | PKR 227.19/vial/unit | 11% above median |
| Zafalexin | Cephalexin | 250 mg | Capsule | 12’s | 005140 | PKR 135.45 | PKR 11.29/capsule | 28% below median |
| Zafalexin | Cephalexin | 125 mg/5 mL | Suspension | 60ml | 011546 | PKR 105.33 | PKR 1.76/mL | 8% below median |
| Zafalexin | Cephalexin | 250 mg/5 mL | Suspension | 60ml | 011547 | PKR 183.82 | PKR 3.06/mL | 7% below median |
| Zafalexin | Cephalexin | 500 mg | Capsule | 12’s | 011548 | PKR 326.30 | PKR 27.19/capsule | 12% below median |
| Zafamax | Azithromycin | 250 mg | Capsule | 6's | 094918 | PKR 258.29 | PKR 43.05/capsule | 13% below median |
| Zafixime | Cefotaxime | 1 g | Injection | 50's | 020202 | PKR 5,219.74 | PKR 104.39/vial/unit | 64% below median |
| Zafixime | Cefotaxime | 1 g | Injection | 1's | 020202 | PKR 300.57 | PKR 300.57/vial/unit | Near median |
| Zafixime | Cefotaxime | 250 mg | IM/IV injection | 50's | 020234 | PKR 2,237.03 | PKR 44.74/vial/unit | 60% below median |
| Zafixime | Cefotaxime | 250 mg | IM/IV injection | 1's | 020234 | PKR 110.88 | PKR 110.88/vial/unit | Near median |
| Zafixime | Cefotaxime | 500 mg | Injection | 50's | 027228 | PKR 3,244.27 | PKR 64.89/vial/unit | 59% below median |
| Zafixime | Cefotaxime | 500 mg | Injection | 1's | 027228 | PKR 121.57 | PKR 121.57/vial/unit | 24% below median |
| Zafquin | Quinine dihydrochloride | 300 mg/mL | Solution for injection | 10 x 2ml | 037384 | PKR 502.67 | PKR 25.13/mL | No comparator |
| Zaftolin | Salbutamol | 0.5 % | Solution | 20ml | 039618 | PKR 87.16 | PKR 4.36/mL | 21% above median |
| Zaftolin | Salbutamol | 2 mg | Syrup | 120ml | 067055 | PKR 88.94 | PKR 0.74/mL | No comparator |
| Zaftolin Inhaler Aerosol | Salbutamol | 100 mcg | Inhaler | 200's | 022553 | PKR 334.24 | PKR 1.67/dose | 16% below median |
| Zafurox | Cefuroxime | 250 mg | Injection | 50's | 022226 | PKR 1,894.25 | PKR 37.89/vial/unit | 30% below median |
| Zafurox | Cefuroxime | 250 mg | Injection | 1’s | 022226 | PKR 57.44 | PKR 57.44/vial/unit | 6% above median |
| Zafurox | Cefuroxime | 750 mg | Injection | 25's | 022227 | PKR 2,990.83 | PKR 119.63/vial/unit | 37% below median |
| Zafurox | Cefuroxime | 750 mg | Injection | 1’s | 022227 | PKR 187.35 | PKR 187.35/vial/unit | Near median |
| Zamlo | Amlodipine | 6.931 mg | Tablet | 20's | 020611 | PKR 275.50 | PKR 13.78/tablet | No comparator |
| Zamlo | Amlodipine + Hydrochlorothiazide | 5 mg + 12.5 mg | Tablet | 2 x 10's | 036339 | PKR 75.50 | PKR 3.78/tablet | 66% below median |
| Zamoclav | Amoxicillin + clavulanic acid | 1000 mg + 200 mg | Injection | 6's | 035383 | PKR 1,706.18 | PKR 284.36/vial/unit | Near median |
| Zamoclav | Amoxicillin + clavulanic acid | 250 mg + 125 mg | Tablet | 1 x 10’s | 035384 | PKR 312.69 | PKR 31.27/tablet | Near median |
| Zamoclav | Amoxicillin + clavulanic acid | 500 mg + 125 mg | Tablet | 1 x 10's | 035385 | PKR 407.31 | PKR 40.73/tablet | Near median |
| Zamoclav | Amoxicillin + clavulanic acid | 125 mg + 31.25 mg | Dry suspension | 60ml | 035386 | PKR 172.56 | PKR 2.88/mL | 16% above median |
| Zamoclav | Amoxicillin + clavulanic acid | 125 mg + 31.25 mg | Dry suspension | 90ml | 035386 | PKR 222.36 | PKR 2.47/mL | 14% below median |
| Zamoclav | Amoxicillin + clavulanic acid | 250 mg + 62.5 mg | Dry suspension | 60ml | 035387 | PKR 271.00 | PKR 4.52/mL | 13% above median |
| Zamoclav | Amoxicillin + clavulanic acid | 250 mg + 62.5 mg | Dry suspension | 90ml | 035387 | PKR 361.33 | PKR 4.01/mL | 11% below median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.